Oruka Therapeutics, Inc. Total Liabilities
Oruka Therapeutics, Inc. total liabilities. Based on the latest financial reports, Oruka Therapeutics, Inc. (ORKA) has total liabilities worth $24.84 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Oruka Therapeutics, Inc. liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Oruka Therapeutics, Inc. (2005–2025)
Total liabilities of Oruka Therapeutics, Inc. from 2005 to 2025. This chart illustrates how Oruka Therapeutics, Inc.'s total liabilities have evolved over time, based on quarterly financial data. Explore ORKA long-term investments to assets to see how much of total assets are deployed in long-term investments.
Oruka Therapeutics, Inc. Competitors by Total Liabilities
The table below lists competitors of Oruka Therapeutics, Inc. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Eagle Materials Inc
NYSE:EXP
|
USA | $2.42 Billion |
|
CSW Industrials Inc
NASDAQ:CSWI
|
USA | $286.63 Million |
|
SFS Group AG
SW:SFSN
|
Switzerland | CHF1.11 Billion |
|
Warehouses de Pauw Comm VA
BR:WDP
|
Belgium | €4.16 Billion |
|
Vista Oil Gas ADR
NYSE:VIST
|
USA | $5.78 Billion |
|
Cogent Biosciences Inc
NASDAQ:COGT
|
USA | $301.24 Million |
|
CNO Financial Group Inc
NYSE:CNO
|
USA | $37.21 Billion |
|
Methanex Corporation
TO:MX
|
Canada | CA$4.29 Billion |
Liability Composition Analysis (2005–2025)
This chart breaks down Oruka Therapeutics, Inc.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see ORKA total assets.
Liquidity & Leverage Metrics
Oruka Therapeutics, Inc. Total Liabilities Ratios Explained
Oruka Therapeutics, Inc. total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 38.51 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.02 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.02 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Oruka Therapeutics, Inc.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Oruka Therapeutics, Inc. (2005–2025)
The table below shows the annual total liabilities of Oruka Therapeutics, Inc. from 2005 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $16.69 Million | +20.94% |
| 2024-12-31 | $13.80 Million | +1540.67% |
| 2023-12-31 | $841.00K | -40.44% |
| 2022-12-31 | $1.41 Million | -63.62% |
| 2021-12-31 | $3.88 Million | -0.69% |
| 2020-12-31 | $3.91 Million | +322.03% |
| 2019-12-31 | $926.00K | +16.77% |
| 2018-12-31 | $793.00K | -62.06% |
| 2017-12-31 | $2.09 Million | -14.17% |
| 2016-12-31 | $2.44 Million | +61.90% |
| 2015-12-31 | $1.50 Million | +8.12% |
| 2014-12-31 | $1.39 Million | -7.45% |
| 2013-12-31 | $1.50 Million | +392.79% |
| 2012-12-31 | $305.00K | -60.39% |
| 2011-12-31 | $770.00K | -44.40% |
| 2010-12-31 | $1.39 Million | -29.34% |
| 2009-12-31 | $1.96 Million | -88.04% |
| 2008-12-31 | $16.39 Million | -69.09% |
| 2007-12-31 | $53.02 Million | -53.72% |
| 2006-12-31 | $114.56 Million | +123.40% |
| 2005-12-31 | $51.28 Million | -- |
About Oruka Therapeutics, Inc.
Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications. Its lead products include ORKA-001 that targets p19 subunit of interleukin-23, which is in phase 2a trial for the treatment of PsO; and ORKA-002 that targets interleukin-17A and interleukin-… Read more